Cannabis Use Disorder, Moderate Clinical Trial
Official title:
Treating Young Adult Cannabis Use Disorder With Text Message-Delivered Peer Network Counseling
Verified date | May 2024 |
Source | The University of Tennessee, Knoxville |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test a text-delivered counseling program to stop or reduce cannabis use among young adults (ages 18 to 25).
Status | Active, not recruiting |
Enrollment | 1077 |
Est. completion date | May 31, 2025 |
Est. primary completion date | May 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 25 Years |
Eligibility | Inclusion Criteria: 1. 18 to 25 years old. 2. use of cannabis three or more days during a typical week. 3. a score of at least eight on the Cannabis Use Disorder Identification Test-Revised 4. a urine specimen positive for cannabis metabolites. 5. a score of at least two on the Mini International Neuropsychiatric Interview: Version 7.0.2 for DSM-V, Substance Use Disorder 6. must live in Tennessee or Colorado Exclusion Criteria: 1. substance abuse treatment during the past three months. 2. lack of access to a text-capable phone. 3. unable or unwilling to commit to six months of follow-up. 4. not fluent in English. |
Country | Name | City | State |
---|---|---|---|
United States | Colorado State University | Fort Collins | Colorado |
United States | University of Tennessee Knoxvile | Knoxville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
The University of Tennessee, Knoxville | Colorado State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in Tetrahydrocannabinol (Delta-9-THC-COOH) levels | Urine THC levels (50ng/mL, 100ng/mL, 200ng/mL, 300ng/mL) will provide a biological measure for current cannabis use. | Baseline, 1 month, 3 months, 6 months | |
Primary | Change in Past 30-Day Cannabis Use | Past-30-day substance use (cannabis, alcohol, tobacco, other drugs) and consequences are measured using the Alcohol, Smoking and Substance Involvement Screening Test | Baseline, 1 month, 3 months, 6 months | |
Secondary | Change in Environmental Risk Assessment | Participants will report using the Ecological Momentary Assessment reporting about Craving (0=none-10= intense), Cannabis Use (0=none-10= a lot), Mood (0=very good-10= very depressed), and Stress (0=no stress-10 = very stressed) on a 10 point scale for each item | Baseline, 1 month, 3 months, 6 months | |
Secondary | Change in Young Adult Social Network Assessment | Participants report information on each their 3 closest friends, representing their egocentric network. Individual friend scores are totaled based on all 8 risky and prosocial items (2-9). Thus, each peer's score has a potential range from -32 to 32, with greater scores indicating a healthier relationship. The total peer network health scores is based on the sum of all 24 risky and prosocial items across all three friends. Assuming three peers per participant, total network quality scores may range from -96 to 96, with lower scores indicating greater network risk and higher scores indicating greater network protection. | Baseline, 1 month, 3 months, 6 months | |
Secondary | Cost Measures | Cost of intervention implementation will be compared to typical treatment cost for cannabis use disorder | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04106336 -
Cortical Excitability and Role of rTMS in Cannabis Use Disorder
|
Early Phase 1 | |
Recruiting |
NCT04964739 -
Gender/Sex & CUD Remission
|
N/A | |
Not yet recruiting |
NCT06225232 -
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
|
Phase 2 | |
Completed |
NCT04923230 -
Pilot Test of Parent-Focused Cannabis-Related Actions and Practices Intervention for Adolescent Marijuana Abuse
|
N/A | |
Completed |
NCT04902092 -
Brain Exercise and Addiction Trial
|
N/A | |
Recruiting |
NCT05064319 -
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
|
Phase 2 |